Logo

Novartis reports positive topline results from the first Phase III trial of Beovu versus aflibercept in patients with diabetic macular edema (DME)

Share this
Novartis reports positive topline results from the first Phase III trial of Beovu versus aflibercept in patients with diabetic macular edema (DME)

Novartis reports positive topline results from the first Phase III trial of Beovu versus aflibercept in patients with diabetic macular edema (DME)

Share this article on WhatsApp, LinkedIn and Twitter



Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions